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ABSTRACT: This study investigates relationships between white matter
hyperintensity (WMH) volume, cerebrospinal fluid (CSF) Alzheimer’s disease
(AD) pathology markers, and brain and hippocampal volume loss. Subjects
included 198 controls, 345 mild cognitive impairment (MCI), and 154 AD
subjects with serial volumetric 1.5-T MRI. CSF Ab42 and total tau were mea-
sured (n5 353). Brain and hippocampal loss were quantified from serial MRI
using the boundary shift integral (BSI). Multiple linear regression models
assessed the relationships between WMHs and hippocampal and brain atro-
phy rates. Models were refitted adjusting for (a) concurrent brain/hippocam-
pal atrophy rates and (b) CSF Ab42 and tau in subjects with CSF data. WMH
burden was positively associated with hippocampal atrophy rate in controls
(P5 0.002) and MCI subjects (P5 0.03), and with brain atrophy rate in con-
trols (P 5 0.03). The associations with hippocampal atrophy rate remained
following adjustment for concurrent brain atrophy rate in controls and MCIs,
and for CSF biomarkers in controls (P5 0.007). These novel results suggest
that vascular damage alongside AD pathology is associated with dispropor-
tionately greater hippocampal atrophy in nondemented older adults.VC 2016
The Authors Hippocampus Published byWiley Periodicals, Inc.
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INTRODUCTION
Atrophy rate, or rate of tissue loss over time, is one of
the markers that reflects disease progression and severity
in Alzheimer’s disease (AD) (Fox et al., 1999; Mungas
et al., 2002; Jack et al., 2005). Hippocampal atrophy is
an early marker of AD pathology (Henneman et al.,
2009; Dubois et al., 2014); rates correlate with
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cerebrospinal fluid (CSF) markers of AD (Hampel et al., 2005;
Schuff et al., 2009) and also with cognitive decline (Jack et al.,
2000). In clinical trials with cognitive outcomes, it has been sug-
gested that sample size can be reduced by enriching the sample
with MCI subjects displaying an atrophy pattern involving the
hippocampus (McEvoy et al., 2010; Yu et al., 2014). However,
atrophic hippocampi and elevated hippocampal atrophy rates
could have multiple causes and may not be solely attributable to
underlying AD pathology.
Cerebral vascular pathology is an important cause of cognitive
decline, and although criteria exist to support a diagnosis of AD
or vascular dementia (Mckhann et al., 1984; Roman et al., 1993),
differentiation of these causes is difficult and mixed pathology is
often present (Schneider et al., 2007). Many AD cases have vascu-
lar damage that is visible on brain imaging (Yoshita et al., 2006)
and apparent at autopsy (Fernando and Ince, 2004; Jellinger and
Attems, 2007). One type of vascular damage appears hypointense
on T1-weighted MRI and hyperintense on T2-weighted imaging;
so-called white matter hyperintensities (WMHs) can be quanti-
fied volumetrically (Prins et al., 2004; Carmichael et al., 2010;
Schmidt et al., 2012). WMH volume is associated with increasing
age (Yoshita et al., 2006), risk of future cognitive decline and
dementia (van der Flier et al., 2005; Carmichael et al., 2010).
WMHs are associated with numerous potentially modifiable cere-
brovascular risk factors (Debette et al., 2011).
Whilst WMHs have been found to associate with longitudinal
brain volume changes (Enzinger et al., 2005; Schmidt et al.,
2005; Barnes et al., 2013), their relevance to medial temporal
lobe (MTL) atrophy is less clear; some have reported positive cor-
relations between WMH and MTL atrophy (Eckerstr€om et al.,
2011; Ye et al., 2014; Crane et al., 2015; Knopman et al., 2015)
and others have not (Du et al., 2006; Rossi et al., 2006; Van De
Pol et al., 2007; Ota et al., 2011; Gattringer et al., 2012; Raji
et al., 2012; Nosheny et al., 2015). Such varying findings may be
due to key differences in the level of cognitive impairment and
vascular risk burden of subjects investigated. Few studies have
investigated across the disease spectrum, and no study has thor-
oughly investigated whether the relationship between WMHs
and hippocampal atrophy rate is explained by the relationship of
AD pathology; which is likely to be important in cognitively
impaired subjects. Improved understanding of the factors that
may underlie hippocampal atrophy rates is crucial for the design
of effective clinical trials aimed at preventing AD where atrophy
rates are used as outcome measures. As trials are being imple-
mented at earlier stages of disease, i.e. in prodromal/presymp-
tomatic individuals, it is important to understand these
interrelationships at the earliest stages.
Following on from a previous study investigating longitudi-
nal whole-brain atrophy rate and WMHs (Barnes et al., 2013),
we investigated the relationship between WMHs and atrophy
of the hippocampus. In order to disentangle the associations of
WMHs and hippocampal atrophy from AD pathology, we also
adjusted our analyses for CSF biomarkers and concurrent brain
atrophy. Our primary measure of atrophy was estimated using
the boundary shift integral (BSI); to see if observed relation-
ships between WMHs and atrophy were substantiated using a
second technique we implemented cross-sectional and longitu-
dinal voxel-based morphometry (VBM). Our specific hypothe-
ses were:
1. WMH volume is related to hippocampal atrophy; greater
WMH is associated with smaller cross-sectional hippocampal
volume and greater longitudinal reduction in hippocampal
volume in control, MCI, and AD subjects.
2. Among brain regions, the hippocampus is differentially vul-
nerable to vascular damage; the relationship between WMH
volume and hippocampal volume change will remain follow-
ing correction for concurrent whole-brain volume change.
3. The hippocampal atrophy is related to vascular damage; the
relationship between WMHs and hippocampal volume change
will remain following adjustment for CSF biomarkers of tau
and amyloid beta 1-42 (Ab42).
VBM analyses were also used to explore whether WMHs were
associated with tissue loss in any extra-hippocampal areas of the
brain.
MATERIALS AND METHODS
Subjects
All data used in this study were obtained from the Alz-
heimer’s Disease Neuroimaging Initiative (ADNI1) database
(http://www.loni.usc.edu/). Launched in 2003, ADNI is a mul-
ticentre, private/public funded longitudinal study investigating
healthy adults, MCI and AD subjects and is led by Principle
Investigator Michael W. Weiner, MD. Its primary goal is to
test whether serial magnetic resonance imaging (MRI), positron
emission tomography (PET), other biological markers, and
clinical and neuropsychological assessment can be combined to
measure AD progression. For up-to-date information, see www.
adni-info.org.
Written informed consent was obtained as approved by the
Institutional Review Board at each participating centre. Partici-
pants took part in baseline clinical, neuropsychometric and
MRI assessments, and periodical assessments thereafter, the fre-
quency of which varied dependent on the diagnostic group.
CSF data were collected in a proportion of subjects, details of
the Ab42 and tau analysis have been described previously
(Shaw et al., 2009). We analysed data from control, MCI and
AD subjects from ADNI1 who had a baseline 1.5-T MRI scan
and at least 1 follow-up 1.5-T MRI scan. Following quality
control 143 scans were excluded (see Figure 1); of which 22%
had a diagnosis of control, 34% of MCI, 27% of AD, and
17% had no diagnostic information available (these scans were
failed at initial visit by LONI).
Image Acquisition and Assessment
The ADNI MRI protocol is described in detail elsewhere
(Jack et al., 2008). Following acquisition, each image
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underwent quality control at the Mayo Clinic (Rochester, MN)
which included protocol compliance check, inspection for clini-
cally significant medical abnormalities, and image quality
assessment. Pre-processing steps using the standard ADNI
image processing pipeline were then applied, including gradient
warping (Jovicich et al., 2006), B1 nonuniformity (Narayana
et al., 1988) and intensity nonuniformity correction (Sled
et al., 1998). These preprocessed images underwent internal
quality control at the Dementia Research Centre, London, UK.
Images with significant motion artefacts causing severe blurring
at the tissue boundaries, were excluded from this study.
Hippocampal and Whole-brain Volumes
and Rates of Change
Imaging data consisted of 0-, 6-, 12-, 18-, 24-, and 36-
month scans where available. Brain volumes were estimated
from the 1.5-T volumetric T1-weighted images using a multi
atlas template brain segmentation method (Leung et al., 2011).
Hippocampal volumes were estimated automatically using a
validated multi atlas template method (Leung et al., 2010).
The left and right hippocampal values were summed together.
The symmetric boundary shift integral (BSI), was used to esti-
mate change directly from scan pairs following segmentation
(Leung et al., 2012), the outcome representing ml of brain or
hippocampus lost during the scan interval. All registrations
were visually checked and excluded in cases of severe motion
or warp due to positional differences. Total Intracranial Vol-
umes (TIV) were calculated using the SPM 12 package (Statis-
tical Parametric Mapping; http://www.fil.ion.ucl.ac.uk/spm) by
summing the grey matter (GM), white matter (WM) and cere-
brospinal fluid (CSF) tissue segmentations (Malone et al.,
2015). The technique used was previously found to correlate
FIGURE 1. Flowchart showing the subject selection process for the cross-sectional and lon-
gitudinal analysis, by diagnostic group. *Twenty-five subjects were additionally excluded which
had no available diagnosis; scans were failed at initial scan by LONI. [Color figure can be
viewed at wileyonlinelibrary.com]
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well with manual segmentation in AD patients (R25 0.940,
95% confidence interval, 95% CI5 0.924–0.953) (Malone
et al., 2015). Voxels representing WMH were included in TIV
estimation. WMH volumes were segmented from baseline PD,
T1, and T2 images using an automated technique, checked by
a trained analyst and edited for gross errors (Schwarz et al.,
2009; Carmichael et al., 2010); these values were downloaded
from the ADNI website (http://www.loni.usc.edu/). WMH vol-
umes were log transformed (base 2) to reduce skewness, its
estimated coefficient thus represents the expected change in
atrophy rate corresponding to a doubling of WMH volume on
the original scale.
Statistical Methods
Group demographics
To test for differences in baseline variables between diag-
nostic groups linear regression (ANOVA) was used for age,
MMSE, total brain volume, total hippocampal volume, TIV
and log2WMH. TIV was used as a covariate when estimating
differences in baseline hippocampal, brain and log2WMH vol-
ume. To look for differences between groups in gender, hyper-
tension, hypercholesterolemia, diabetes, smoking, and presence
of an APOE e4 allele, Fisher’s exact test was used.
Cross-sectional hippocampal and whole
brain volumes
All cross-sectional and longitudinal analyses were performed
for the whole-brain and hippocampus, separately in each diag-
nostic group.
To analyse the cross-sectional relationship between volumes
and baseline WMH volume a multiple linear regression was
performed with baseline volume (hippocampal or whole-brain)
as the outcome, log2WMH as the predictor variable, and TIV
and gender as covariates.
Longitudinal hippocampal and whole
volume changes
To analyse the association between baseline log2WMH volume
and whole-brain and hippocampal atrophy rates, linear mixed
effects models were fitted. The dependent variable was the BSI
(ml of brain or hippocampus lost during the scan interval). Inter-
val (years) between baseline and follow-up scans was included as
a fixed effect such that the resulting coefficient estimated from
the model represents the change of volume in ml per year. Inter-
val was also included as a random effect to permit between sub-
ject heterogeneity in atrophy rate; the trajectories of atrophy rate
for each individual were able to vary, to allow for unknown fac-
tors which influence atrophy rate between individuals. An inter-
action between baseline log2WMH volume and interval allowed
for the former to influence mean atrophy rate. No intercept was
included in the model; ensuring that the estimated atrophy rate
over a scan interval of zero is zero.
In order to estimate the association between baseline log2
WMH and hippocampal volume change whilst adjusting for
whole-brain atrophy (and vice versa), a joint mixed effects
model was constructed, see Manning et al., 2014. This model
permits the random effects dictating the rates of hippocampal
and whole-brain atrophy rates to be correlated. It accommo-
dates missing values under the missing at random assumption
(Manning et al., 2014). Models were additionally run allowing
for CSF biomarkers to modify atrophy rates. In additional
analyses age and vascular risk factors (VRFs) were added to the
longitudinal models. These covariates were added as interaction
terms with interval, to investigate whether their addition affect-
ed relationships between WMH and hippocampal atrophy rate.
The VRFs added were history of hypertension, hypercholester-
olemia, diabetes, smoking, and APOE genotype (presence of
one or more APOE e4 alleles). As the dependent variable rep-
resents absolute volume change, all analyses were adjusted for
TIV, also using an interaction with interval. We also investigat-
ed whether the effect of WMH on atrophy rates was depen-
dent on TIV to test whether subjects with the same volume of
WMH, but different TIVs (serving as a proxy for head size)
have differing relationships between WMH and atrophy. For
this an interaction term between TIV, WMH, and interval was
added to the previous mixed models of WMH and TIV with
atrophy rate as outcome. Consequently both atrophy rate and
WMH were adjusted for TIV; the former through the main
effect of TIV and the latter with the WMH-TIV interaction
term. The overall effect of WMH on atrophy rates with the
TIV-WMH interaction was tested by comparing models with
the WMH-TIV interaction and WMH as predictors, versus
models without these coefficients using a likelihood ratio test.
As most subjects had multiple BSI values from their longitu-
dinal visits, we generated a single atrophy rate estimate per per-
son from a mixed effects regression model without adjustment
for covariates except scan interval; these were used to generate
longitudinal plots. Postestimation linear predictions (mean rate
plus predicted individual random effect) of rate were plotted
against log2WMH for visualization purposes. Simple regression
lines were overlaid on the plots.
Voxel-based morphometry (VBM)
Cross-sectional and longitudinal VBM was used to assess the
correlation between log2WMH and patterns of volume change in
GM and WM. Subjects with a usable baseline and 24-month
scan pair were used, the VBM dataset thus represents a propor-
tion of the original BSI dataset (456 subjects of 697 used for
BSI). For cross-sectional analysis, baseline images were first rigid-
ly reorientated to Montreal Neurological Institute (MNI) space,
segmented into GM, WM and CSF, and normalised to a group-
wise space (DARTEL). Segments were smoothed with a 6mm
Gaussian kernel and a groupwise mask was created for analysis
(Ridgway et al., 2009). See Supporting Information Methods for
more information.
For longitudinal analysis, baseline and 24-month images
were first independently rigidly reoriented to MNI space.
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Using SPM12’s Pairwise Longitudinal Registration tool baseline
and 24-month images were registered, producing a midpoint
average image (Ashburner and Ridgway, 2013). Voxel-wise vol-
ume change maps were quantified as the difference between
follow-up and baseline Jacobian maps (which measure the vol-
ume change relative to, and in the space of, the average image)
divided by the scan interval. Segmentation and DARTEL nor-
malization as above were performed using the midpoint average
image. Volume change maps were smoothed using Tissue
Weighted Smoothing, separately for GM and WM. All tests
were thresholded to correct for multiple comparisons, control-
ling the Family Wise Error (FWE) at a level of p< 0.05. See
Supporting Information Methods for more information.
RESULTS
Group Demographics
Data from 840 subjects were downloaded from the ADNI
website. Subjects were excluded if they had a baseline scan
only, were missing WMH values and/or failed internal quality
control (see Image Acquisition and Assessment section), see
Figure 1. Table 1 shows demographic and image summary sta-
tistics from the 697 subjects included in the analysis. There
were statistically significant differences between the three diag-
nostic groups in gender distribution, with a greater proportion
of male subjects in the MCI group. Subject groups also dif-
fered in MMSE, total brain volume, total hippocampal vol-
ume, APOE genotype and WMH volume at baseline in a
manner consistent with MCI and AD. See Supporting Infor-
mation Results Table 1 for demographic differences in the
VBM subset.
Cross-Sectional Analyses
Table 2 shows the partial regression coefficients for the asso-
ciation between WMHs and cross-sectional brain and hippo-
campal baseline volumes. Average brain volumes calculated
from the model were 1,071 ml in control subjects, 1,068 ml in
MCI subjects and 1,024 ml in AD subjects for females with
mean TIV and WMH values. Average hippocampal volumes
were 5.2 ml for controls, 4.4 for MCI subjects, and 3.9 ml for
AD subjects for females with mean TIV and WMH values.
There was strong evidence of an association between WMH
burden and baseline brain volume in MCI and AD groups,
after adjusting for gender and TIV. Each doubling of WMH
burden was estimated to be associated with a smaller brain vol-
ume of 6.0 ml (95% CI 3.4–8.5), and 6.6 ml (2.4–10.9) in
the MCI and AD groups, respectively. In controls there was
borderline statistically significant evidence of an association,
with a doubling of WMH associated with a brain volume of
3.4 ml (0.1–6.8) less than average brain volume. There was
strong evidence of an association between WMHs and baseline
hippocampal volume in all three groups, with a doubling of
WMH volume associated with a 0.06 (0.02–0.10), 0.08 (0.05–
0.12), and 0.09 ml (0.03–0.15) reduction in the average con-
trol, MCI and AD hippocampal volumes respectively. There
were no significant relationships between gender and either
whole-brain or hippocampal volume.
TABLE 1.
Subject Demographics and Basic Imaging Information
Controls MCI AD
p value across
groups
N (total5 697) 198 345 154
Age at baseline (yr) 75.9 (5.1) 75.0 (7.2) 75.0 (7.7) 0.3
Percentage male 52.5 63.2 53.9 0.03
MMSE at baseline, /30 29.1 (1.0) 27.0 (1.8) 23.4 (1.9) <0.001
Length of follow-up (yr); minimum, maximum 2.6 (0.8); 0.5, 3.7 2.3 (0.8); 0.5, 3.5 1.7 (0.6); 0.5, 3.1 <0.001
BSI measurements per subject, No.; minimum,
maximum
3.2 (0.9); 1, 4 3.6 (1.3); 1, 5 2.3 (0.8); 1, 3 <0.001
Total brain volume (ml) 1,068 (103) 1,061 (115) 1,022 (115) <0.001a
Total hippocampal volume (ml) 5.2 (0.7) 4.5 (0.8) 3.9 (0.9) <0.001a
Total intracranial volume (ml) 1,445 (134) 1,468 (146) 1,450 (163) 0.2
White matter hyperintensity (ml); log2WMH (ml) 0.24 (0.5); 22.37 (2.3) 0.28 (0.6); 22.08 (2.4) 0.40 (1.0); 21.37 (2.2) <0.001
a
Percentage hypertensive 42 50 52 0.1
Percentage hypercholesteraemic 25 30 36 0.1
Percentage diabetic 6 7 6 0.8
Percentage APOE e4 carrier 26 55 69 <0.001
Percentage smoker (past or current) 40 41 40 1.0
Values are mean (SD) unless reported. White matter hyperintensity values reported as median with IQR.
aAdjusted for TIV. APOE e4 carrier refers to individuals with one or more APOE e4 alleles.
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Longitudinal Analyses
Table 3 shows the partial regression coefficients for the asso-
ciation between baseline WMHs, brain atrophy rates and hip-
pocampal atrophy rates. Figure 2 shows scatterplots of whole-
brain and hippocampal atrophy rates against log2WMH. Mean
atrophy rates of the whole-brain were estimated to be 6.3
(5.8–6.8), 10.7 (10.0–11.4), 15.1 (14.0–16.1) ml/year for con-
trol, MCI and AD subjects respectively for subjects with mean
TIV values. Average hippocampal atrophy rates were estimated
to be 0.07 (0.06–0.07) ml/year in the control group, 0.1
(0.13–0.15) ml/year in the MCI group, and 0.2 (0.19–0.22)
ml/year in AD subjects with mean TIV values. There was
some evidence of an association between baseline WMHs and
subsequent whole-brain atrophy rate in controls, with each
doubling in WMH volume associated with an estimated
increase in atrophy rate of 0.3 ml/year (0.03–0.5). There was
stronger evidence for an association with hippocampal atrophy
in controls, with each doubling of WMH volume estimated to
increase atrophy by 0.005 ml/year (0.002–0.009). The associa-
tion between WMHs and whole-brain atrophy in controls was
substantially reduced after adjusting for concurrent hippocam-
pal atrophy, with the independent effect reduced to 0.06 ml/
year (from 0.3 ml/year), and was no longer statistically signifi-
cant after adjustment. The association between WMHs and
hippocampal atrophy was also materially reduced in controls
TABLE 2.
Results From the Regression Models Assessing the Relationship Between Cross-Sectional Brain and Hippocampal Volumes (Outcome
Measures) and log2WMH Volume (Predictor)
Controls MCI AD
N 198 345 154
Mean brain volume adjusted for WMH, TIV and
gender (ml)
1,071.1 1,067.6 1,024.0
Mean hippocampal volume
adjusted for WMH, TIV and gender (ml)
5.2 4.4 3.9
Association between WMH and baseline brain
volume
23.41 (26.76 to 20.06);
p 5 0.05
25.95 (28.48 to 23.42);
p < 0.001
26.61 (210.87 to 22.35);
p 5 0.003
Association between WMH and baseline
hippocampal brain volume
20.06 (20.10 to 20.02);
p 5 0.003
20.08 (20.12 to 20.05);
p < 0.001
20.09 (20.15 to 20.03);
p 5 0.003
Estimates are shown with 95% confidence intervals for an increase in volume (ml) for a doubling of WMH, conditional on intracranial volume and gender.
TABLE 3.
Results From the Regression Models Assessing the Relationship Between Atrophy Rates (Outcome Measures) and log2WMH Volume
(Predictor)
Controls MCI AD
N 198 345 154
Rate of whole-brain atrophy (ml/yr) 6.31 (5.82 to 6.79)
p < 0.001
10.69 (10.00 to 11.37)
p < 0.001
15.08 (14.02 to 16.14)
p < 0.001
Rate of hippocampal atrophy (ml/yr) 0.07 (0.06 to 0.07);
p < 0.001
0.14 (0.13 to 0.15);
p < 0.001
0.20 (0.19 to 0.22);
p < 0.001
Association between WMH and whole-brain
atrophya
0.3 (0.03 to 0.5);
p 5 0.03
0.1 (20.2 to 0.4); P 5 0.4 0.06 (20.4 to 0.5);
p 5 0.8
Association between WMH and hippocampal
atrophya
0.005 (0.002 to 0.009);
p 5 0.002
0.005 (0.0004 to 0.009);
p 5 0.03
20.0005 (20.008 to 0.007);
p 5 0.9
Association between WMH and whole-brain
atrophy rate adjusted for hippocampal atrophy
rateb
0.06 (20.1 to 0.3);
p 5 0.5
20.1 (20.3 to 0.1);
p 5 0.3
0.07 (20.3 to 0.5);
p 5 0.7
Association between WMH and hippocampal
atrophy rate adjusted for whole-brain atrophy
ratec
0.003 (0.0003 to 0.006);
p 5 0.03
0.003 (0.0004 to 0.007);
p 5 0.03
20.0009 (20.007 to 0.005);
p 5 0.8
aEstimates are shown for increase in atrophy rate (ml/year), with 95% confidence intervals: for a doubling of WMH, conditional on intracranial volume.
bEstimates are shown for increase in atrophy rate (ml/year), with 95% confidence intervals: for a, conditional on intracranial volume and hippocampal atrophy
rate
cEstimates are shown for increase in atrophy rate (ml/year), with 95% confidence intervals: for a conditional on intracranial volume and whole-brain atrophy rate.
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after adjusting for concurrent whole-brain atrophy, although
there remained statistically significant evidence of an indepen-
dent association, with each doubling of WMH volume associ-
ated with a 0.003 ml/year (0.0003–0.006) increase in
hippocampal atrophy rate. In patients with MCI, the associa-
tion between WMHs and hippocampal atrophy was also
reduced after adjustment for concurrent whole-brain atrophy,
with each doubling of WMHs associated with a 0.003 ml/year
(0.0004–0.007) increase in hippocampal rate. Other associa-
tions were not statistically significant.
CSF Subset Analyses
Associations between log2WMH and atrophy
rates following CSF biomarker adjustment
Table 4 shows the results from the biomarker analyses. The
relationship between whole-brain and hippocampal atrophy
and log2WMH remained statistically significant in the control
group following adjustment for CSF biomarkers, with a dou-
bling of WMH volume associated with an increase in atrophy
rate of 0.3 ml/year (0.07–0.6) for the whole-brain and
0.008 ml/year (0.004–0.01) for the hippocampus. There was
no evidence of an association between WMHs and hippocam-
pal atrophy rate after CSF biomarker adjustment in MCI sub-
jects. Importantly, in the control group a strong association
between WMHs and hippocampal atrophy rate survived fol-
lowing adjustment for concurrent whole-brain atrophy rate and
CSF biomarkers, with a doubling in WMH volume estimated
to increase hippocampal atrophy rate by 0.005 ml/year (0.001–
0.009). However, it did not remain statistically significant in
the subset of MCI patients with CSF measures, in contrast to
findings in the whole group unadjusted for CSF biomarkers.
Associations between Ab42 and atrophy rates
adjusted for tau and log2WMH
In the CSF biomarker subset, after adjustment for tau and
log2WMH, lower baseline CSF Ab42 was associated with
increased whole-brain atrophy rates in controls with a 10 pg/
ml decrease in concentration of Ab42 associated with an
increase in whole-brain atrophy rate of 0.2 ml/year (0.06–0.3).
FIGURE 2. Plots showing the relationship between baseline log2WMH, whole-brain (a),
and hippocampal atrophy rate (b) in control, MCI and AD subjects. Individual predicted atro-
phy rate estimated from mixed model with predictors of BSI (tissue loss at all scanning inter-
vals) and scan interval. [Color figure can be viewed at wileyonlinelibrary.com]
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In MCI patients lower Ab42 was also associated with an
increased whole-brain atrophy rate; with a 10 pg/ml decrease
in concentration of Ab42 estimated to increase atrophy rate by
0.4 ml/year (0.2–0.6). In MCI patients evidence was observed
for an association between Ab42 and hippocampal atrophy,
with a 10 pg/ml decrease in Ab42 associated with an increase
in atrophy rate of 0.006 ml/year (0.003–0.009).
Associations between CSF tau and atrophy rates
adjusted for Ab42 and log2WMH
In controls there was evidence that increasing CSF tau was
associated with an increase in hippocampal atrophy rate adjust-
ed for Ab42 and log2WMH, with a 10 pg/ml increase in tau
associated with an increase in atrophy rate of 0.005 ml/year
(0.002–0.009). There were no other statistically significant
associations.
Associations Between log2WMH and Atrophy
Rates Adjusted for Age and Vascular
Risk Factors
Following age and VRF adjustment, WMH volume
remained associated with hippocampal atrophy in controls and
MCI patients, with a doubling of WMH burden associated
with an increase in hippocampal atrophy rate of 0.004 ml/year
(0.001–0.008) for controls and 0.007 ml/year (0.003–0.012)
for MCI patients; although for controls this was not statistically
significant following correction for concurrent whole-brain
atrophy, see Supporting Information Table 2. However, in
models adjusting for CSF Ab42, CSF tau, VRFs and age,
WMH volume was found to be associated with hippocampal
atrophy after adjusting for concurrent whole-brain atrophy;
with a doubling of WMH volume associated with an increase
in atrophy rate of 0.005 ml/year (0.001–0.009) see Supporting
Information Table 3.
TABLE 4.
Results From the Regression Models Assessing the Relationship Between Atrophy Rates (Outcome Measures) and log2WMH Volume, CSF Ab,
and tau (Predictors)
Controls MCI AD
N 100 167 86
Rate of whole-brain atrophy (ml/yr) 6.25 (5.64 to 6.86);
p < 0.001
11.46 (10.53 to 12.40);
p < 0.001
14.48 (13.18 to 15.79);
p < 0.001
Rate of hippocampal atrophy (ml/yr) 0.06 (0.05 to 0.07);
p < 0.001
0.15 (0.14 to 0.16);
p < 0.001
0.19 (0.17 to 0.21);
p < 0.001
Association between WMH and whole-brain
atrophy ratea
0.3 (0.07 to 0.6);
p 5 0.01
0.2 (20.2 to 0.6);
p 5 0.4
20.2 (20.8 to 0.3);
p 5 0.4
Association between WMH and hippocampal
atrophy ratea
0.008 (0.004 to 0.01);
p < 0.001
0.004 (20.002 to 0.01);
p 5 0.2
20.0008 (20.008 to 0.007);
p 5 0.8
Association between CSF Ab42 and whole-brain
atrophy rateb
20.2 (20.3 to 20.06);
p 5 0.004
20.4 (20.6 to 20.2);
p < 0.001
20.3 (20.6 to 0.03);
p 5 0.08
Association between CSF Ab42 and hippocampal
atrophy rateb
20.001 (20.003 to 0.0008);
p 5 0.2
20.006 (20.009 to 20.003);
p < 0.001
20.004 (20.008 to 0.0003);
p 5 0.07
Association between CSF tau and whole-brain
atrophy ratec
0.2 (20.04 to 0.4);
p 5 0.1
0.04 (20.2 to 0.2);
p 5 0.7
0.1 (20.1 to 0.3);
p 5 0.4
Association between CSF tau and hippocampal
atrophy ratec
0.005 (0.002 to 0.009);
p 5 0.006
0.002 (20.001 to 0.005);
p 5 0.3
20.001 (20.004 to 0.002);
p 5 0.6
Association between WMH and whole-brain
atrophy rate adjusted for hippocampal atrophy
rated
0.1 (20.1 to 0.3);
p 5 0.4
20.004 (20.3 to 0.3);
p> 0.9
20.2 (20.7 to 0.3);
p 5 0.5
Association between WMH and hippocampal
atrophy rate adjusted for whole-brain atrophy
ratee
0.005 (0.001 to 0.009);
p 5 0.007
0.002 (20.002 to 0.007);
p 5 0.4
20.0004 (20.007 to 0.007);
p 5 0.9
aEstimates are shown with 95% confidence intervals for increase in atrophy rate in ml/year: for a doubling of WMH conditional on intracranial volume, CSF
Ab42 and tau.
bEstimates are shown with 95% confidence intervals for increase in atrophy rate in ml/year: for a 10 pg/ml increase in Ab conditional on intracranial volume,
log2WMH volume and CSF tau.
cEstimates are shown with 95% confidence intervals for increase in atrophy rate in ml/year: for a 10 pg/ml increase in tau, conditional on intracranial volume,
Ab42 and log2WMH volume.
dEstimates are shown with 95% confidence intervals for increase in atrophy rate in ml/year: for a doubling of WMH conditional on intracranial volume, CSF
Ab42 and tau, hippocampal atrophy rate.
eEstimates are shown with 95% confidence intervals for increase in atrophy rate in ml/year: for a whole-brain atrophy rate.
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Association Between log2WMH and Atrophy
Rate with a TIV-WMH Interaction Term
Following the addition of an interaction term between
WMH and TIV all significant associations of WMH to atro-
phy rate remained, see Supporting Information Table 4. The
TIV-WMH interaction term was significant for the whole-
brain of controls; at the mean TIV a doubling of WMH was
found to be associated with an increase of 0.3 (0.07–0.51) ml/
year in atrophy rate. This association between WMH and atro-
phy rate is then estimated to increase by 0.2 (0.01–0.38) ml/
year for each 100 ml increase in TIV.
VBM Results
Regions of reduced volume, or volume change, associated
with WMH were observed in the precentral sulcus in all
groups; the postcentral sulcus and superior frontal lobe for
MCI and AD patients; and in the occipital lobes for control
and MCI participants; see Table 5 for cluster locations, vol-
umes, and p values, and Supporting Information for t and
effects maps.
DISCUSSION
In this study, we found novel evidence that WMHs were
associated with disproportionately greater hippocampal atrophy
in controls and MCI subjects relative to whole-brain atrophy.
Further, the associations in control subjects remain statistically
significant when adjusting for CSF Ab42 and tau in those sub-
jects in whom CSF was taken (50% total cohort). In separate
analyses for each structure we found a higher baseline WMH
TABLE 5.
Cross Sectional and Longitudinal VBM Results
Cross-sectional Longitudinal
Location k p Location k p
C GM Left precentral gyrus
Left inferior temporal lobe
64
51
0.002
0.004
No results found
WM No results found Left superior frontal lobe 50 0.03
MCI GM Left parietal operculum 615 <0.001 Left occipital lobe 130 0.005
Left thalamus, hypothalamus 865 <0.001 Right postcentral gyrus 53 0.009
Right central sulcus 381 <0.001 Right occipital lobe 101 0.01
Left central sulcus 191 0.001 Right superior frontal lobe 53 0.01
Right parietal operculum 97 0.002 Right postcentral gyrus 54 0.01
Right occipital 56 0.01
Right postcentral gyrus 97 0.01
Right cerebellum 232 0.02
Right cerebellum 75 0.02
Right superior frontal lobe 48 0.02
Left superior frontal lobe 31 0.02
WM No results found Right superior frontal lobe 1083 0.003
Left superior frontal lobe 142 0.01
Left precuneal 242 0.01
Right precentral sulcus 116 0.02
Right postcentral sulcus 80 0.02
AD GM Left occipital lobe 90 <0.001 No results found
Left occipital lobe 214 0.001
Right occipital lobe 284 0.001
Left central sulcus 42 0.003
Left hippocampus 303 0.004
Right central sulcus 47 0.005
Left occipital lobe 48 0.009
WM No results found No results found
Results from voxel based morphometry (VBM) correlating log transformed white matter hyperintensity (log2WMH) with voxel volume adjusted for gender and
total intracranial volume (cross sectional analysis), or log2WMH with change in voxel volume adjusted for TIV (longitudinal analysis). Tables show the cluster
locations, size in number of voxels (k) and associated p value; analyses were corrected for multiple comparisons (Family Wise Error); clusters greater than 30 voxels
and with a P value of >0.05 are reported. Table shows clusters in the grey matter and white matter for each control, MCI and AD subjects, from longitudinal
and cross sectional VBM.
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volume was associated with a greater atrophy rate of the
whole-brain and hippocampus, and of the hippocampus in
MCIs. We also found evidence that increased WMH volume is
associated with smaller cross-sectional whole-brain and hippo-
campal volumes across subject groups in ADNI1.
To our knowledge this is the first study to have reported an
association between WMHs and longitudinal hippocampal loss
occurring in cognitively normal older individuals after adjust-
ing for AD pathology through measures of CSF Ab42 and tau.
In controls this observed relationship was equivalent to an
8.5% increase in mean hippocampal atrophy rate for a dou-
bling of WMH volume in individuals with the average TIV,
whole-brain atrophy rate, and WMH burden. The dispropor-
tionate hippocampal loss observed may be due to the selective
vulnerability of this region to WMHs or other shared risk fac-
tors for WMHs. Notably, the cause of such a relationship is
not fully explained by AD pathology, at least as assessed by sin-
gle CSF measurements, since relationships between atrophy
and WMHs in normal individuals persist after adjustment for
CSF Ab42 and tau markers. As ADNI is a study designed to
emulate a clinical trial, this is a finding of significant interest.
The finding that WMHs are associated with atrophy indepen-
dently of AD pathology (as measured by CSF biomarkers)
mean a successful intervention targeting AD related pathology
in controls with preclinical AD may not be as effective at slow-
ing atrophy if there is concurrent white matter damage.
Associations between baseline WMHs and whole-brain atro-
phy rate reached statistical significance only in controls and not
in MCI subjects. This may reflect the inclusion criteria for
ADNI to select amnestic presenting MCI patients, and for
screening out those with significant vascular pathology. As a
result those more likely to have predominantly AD pathology
causing their cognitive impairment may have been selected.
Further, this may be because WMHs have a greater association
with structural changes early in the disease process, and a great-
er role for Ab42 and tau in the early symptomatic AD stages.
Although cross-sectional data indicates that the greatest asso-
ciation between WMHs and atrophy is in the AD group, lon-
gitudinal data show no evidence of an association between
baseline WMH volume and subsequent atrophy in AD sub-
jects. Longitudinal relationships between WMH and atrophy
rates were detected in controls. A possible explanation for these
observations is that WMHs exert a similar influence on atro-
phy rates in control and AD subjects but that this is difficult
to detect in the AD group due to large inter-subject heteroge-
neity and lower power due to smaller group size. Factors caus-
ing variance in atrophy rates in AD are yet to be fully
determined but may include inflammatory factors, disease
duration and genetics. Alternatively WMHs may have a prima-
ry influence on progressive atrophy early in the disease course
and less at later stages. A notable caveat of this latter interpre-
tation is that these similarly aged diagnostic groups may not
represent a continuum across the disease spectrum; a 75-year-
old control with a high WMH burden destined to develop AD
may follow a different disease course from a 75-year-old with
established disease. Larger group sizes and continuation of
longitudinal data collection over longer periods will provide
more information to address the nature of the relationship
between WMHs and atrophy rates in the presence and absence
of AD.
Our results are in line with previous studies showing that
WMHs are associated with reduced grey matter volume (Rossi
et al., 2006; Wen et al., 2006; Raji et al., 2012; Lambert et al.,
2015) and progressive atrophy (Enzinger et al., 2005a; Barnes
et al., 2013). However, unlike Rossi et al. and Raji et al., we
did not find volume loss associated with WMH volume in the
prefrontal cortex in our VBM analyses (Rossi et al., 2006; Raji
et al., 2012). Other studies have also found smaller hippocam-
pal volumes in subjects with higher WMH volumes (de Leeuw
et al., 2004; den Heijer et al., 2005), whilst others using longi-
tudinal measures of hippocampal atrophy have not (Du et al.,
2006; Nosheny et al., 2015). In a recent study Nosheny et al.
did not find a relationship between WMH and hippocampal
atrophy rate in control or MCI subjects using multivariable
models, despite also using ADNI1 subjects. This key difference
may be due to the use of subjects with longitudinal MRI and
also either CSF Ab42, or amyloid positron emission tomogra-
phy (PET) imaging data collected at any point over a 4-year
period, including the transition in phase to ADNIGO or
ADNI2 (Nosheny et al., 2015). This length of follow-up may
be important; in our study we have found that those who have
at least a 24-month scan have higher brain and lower WMH
volume than subjects who drop out before 24 months (see
Supporting Information data). Alternatively, our findings may
be due to our inclusion of tau as a covariate as well as Ab42,
or use of BSI rather than Freesurfer methods; hippocampal
measures have been previously been found to be highly variable
between techniques, likely due to differing definitions of the
region (Cash et al., 2015).Our study extends these findings by
showing that greater longitudinal hippocampal atrophy is seen
in control subjects with a higher burden of WMHs, after
adjusting for concurrent brain atrophy and CSF biomarkers.
That statistically significant relationships between atrophy
rates and WMHs are predominantly seen in control subjects is
in agreement with previous longitudinal studies showing
changes in WM before grey matter changes occur, observed
both at the macroscopic level through acceleration in growth of
WMHs (Silbert et al. 2012) and microscopically through
changes in water diffusion in WM detected by diffusion tensor
imaging (DTI) (Zhuang et al., 2012). This is in concordance
with the two hit vascular hypothesis for AD; that vascular risk
factors may confer blood-brain-barrier dysfunction and oligae-
mia in the first instance, initiating a second cascade of events
involving amyloid and tau, neuronal dysfunction, degeneration,
cognitive decline and eventual dementia (Zlokovic, 2011).
The observed hippocampal atrophy may be driven by an
independent direct effect of WMH, and/or by vascular risk fac-
tors and ageing processes which also cause WMH. Notably,
associations between the hippocampal atrophy and WMH
remained in controls following adjustment for VRFs and age
in our analyses, suggesting WMH may have an effect on atro-
phy rate over and above the influence of the effects of the
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VRFs investigated in this study. Specific vulnerability of the
hippocampus to WMH was suggested by the fact that an asso-
ciation was still observed after adjusting for concurrent whole-
brain atrophy, CSF biomarkers, age and VRFs.
The dual vulnerability of the hippocampus to vascular and
AD pathology is congruent with studies demonstrating the sus-
ceptibility of the hippocampus to hypertension in midlife (Korf
et al., 2004) and hypoxia (Kirino and Sano, 1984; Di Paola
et al., 2008; Horstmann et al., 2010). Alternatively WMH may
contribute to atrophy through cortical disconnection (Villain
et al., 2008; Lee et al., 2010) and/or WMHs in tracts serving the
hippocampus may lead to axonal loss and subsequent atrophy via
Wallerian degeneration (Von Bohlen und Halbach and Unsicker,
2002; Schmidt et al., 2011). Whether the observed link between
hippocampal atrophy and WMH is dependent on TIV (a pro-
dromal marker of brain size) is yet unknown and presents an
interesting question for future research.
We have found that the relationship between WMH volume
and atrophy persists when adjusting for CSF biomarkers of AD
pathology in controls. Whilst a separate vascular means of tissue
loss is plausible, Ab42, tau, and WMHs may be intimately related.
There is evidence from animal models that following ischaemia
there is an acute increase in secretions of Ab (Pluta et al., 2013),
and following resuscitation from cardiac arrest in humans, Zetter-
berg et al. found a time-dependent increase in Ab42 levels detected
in the blood (Zetterberg et al., 2011). Recent work has shown that
MCI participants with low tau, but higher regional WMHs, dis-
play increased entorhinal cortex atrophy (Tosto et al., 2015).
Finally, poor vascular health may contribute to Ab42 and tau
deposition due to impaired clearance of toxins from the brain via
the perivascular drainage pathways (Tarasoff-Conway et al., 2015).
Our VBM analyses did not find a longitudinal association
between WMHs and atrophy in the hippocampal region but
did find significant positive associations in other cortical
regions. That we did not find statistically significant evidence
of an association between hippocampal atrophy rate and
WMHs in these analyses may be due to the lower WMH bur-
den and slower progression in the subset with a usable baseline
and 24 month scan pair (see Supporting Information Table 1),
or of the difficulty of this technique at detecting specific hippo-
campal change. Those with unusable 24-month scans had low-
er brain volumes and higher WMH volumes at baseline than
those who had good quality 24-month imaging. Other studies
have found such selection biases: Leung et al. found, within a
similar subset of ADNI, a trend that suggested controls and
AD subjects with higher brain atrophy rates between baseline
and 12 months would be less likely to have an available 12 to
24 month scan pair (Leung et al., 2013). This suggests our
VBM findings may be biased toward those with a less aggres-
sive disease course and less white matter disease. In addition,
VBM was performed on a single (baseline–24 months) scan
pair and BSIs on all available scan pairs including those who
dropped out before 24 months, thus reducing power with
which to detect an association with VBM.
VBM analyses showed subjects with higher WMH volume
had lower cross-sectional volumes in somatosensory and motor
cortices in control and subjects, and greater longitudinal change
in MCI patients. These regions are among the last areas to be
affected by amyloid plaques and neuritic tangles in AD (Brun
and Englund, 1981; Braak and Braak, 1991), suggesting tissue
loss in these regions is more likely to be related to shared vascular
processes underlying WMH burden than AD pathology. Atrophy
in motor regions related to WMHs is also supported by clinical
symptoms of impaired gait and motor control experienced by
individuals with a high burden of WMHs, as reported previously
(Longstreth et al., 1996; Whitman et al., 2001; Silbert et al.,
2008). Gait disturbance may be caused by involvement of peri-
ventricular WMHs disrupting descending and ascending sensory
and motor pathways (Longstreth et al., 1996).
Limitations of this study are that there are biases in the study
sample which may limit generalisability to a wider population.
These associations were found in healthy ADNI controls who
were free from overt cardiovascular disease (subjects with a
Hachinski score 4 included), were well educated and of a high
socioeconomic status. As such these findings may be different
compared to a community population, who may have a greater
vascular burden. The imaging data for this set of ADNI did not
acquire T2-weighted fluid attenuated inversion recovery (FLAIR)
MRI which gives a more accurate estimation of white matter
hyperintensity volume. Our measures may not be optimal as it is
becoming clearer that novel techniques such as diffusion MRI
can detect subtle white matter changes before they become visible
on standard structural MRI (de Groot et al., 2013). Additionally
we looked at a global, total measure of WMHs and did not look
at subtypes of WMH, such as deep or periventricular, nor did we
split by regions, such as frontal or parietal WMHs; these may
have given differing results (Tosto et al., 2015). Lastly, to fully
investigate the impact of small vessel disease on atrophy rates,
further markers of small vessel disease, such as lacunes and micro-
bleeds, and larger subject sizes allowing the unpicking of relation-
ships between vascular covariates, imaging markers of vascular
damage and atrophy would be required.
In summary, our study indicates that WMH load is associat-
ed with hippocampal atrophy in healthy older adults after
adjusting for CSF measures of AD pathology. These results
show that baseline WMH can partially explain variability in
atrophy rates; therefore clinical trials to target AD pathology in
at-risk populations may increase power with which to detect a
treatment effect by stratifying or adjusting for WMH. Further
longitudinal investigation will be required to determine wheth-
er WMH are an important step on the pathway to atrophy
and cognitive impairment. If they are, subsequent preventative
approaches designed to reduce the risk of developing WMH
could therefore potentially decrease the incidence or delay the
onset of atrophy and cognitive impairment.
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